Delivery Order SPE2DR25D3015-SPE2DR26F4FZ9
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $7,748.39 to AmerisourceBergen Drug Corp for the supply of Erleada 240 mg tablets (30-count units) on December 15, 2025. This firm fixed-price delivery order, which is expected to be completed by January 7, 2026, represents a non-competitively set-aside award and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. The award falls under AmerisourceBergen Drug Corp's larger Indefinite Delivery...
- The Defense Logistics Agency awarded a $7,558.78 delivery order to AmerisourceBergen Drug Corp on July 28, 2025, for the supply of Erleada 60 mg tablets (120 count). This firm fixed price contract, with an ultimate completion date of August 18, 2025, represents a non-set-aside competitive award. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on October 15, 2025, for the supply of Erleada 240 mg tablets in quantities of 30 units. This is a firm fixed-price delivery order with a ceiling value of $7,352.49 and an ultimate completion date of November 5, 2025. The contract carries no set-aside designation, indicating it was competitively awarded. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical...
- The Defense Logistics Agency awarded a delivery order valued at $7,558.79 to AmerisourceBergen Drug Corp for the supply of Erleada 60 mg tablets (120-count units) on October 29, 2025, with completion scheduled for November 20, 2025. This competitively awarded, firm fixed-price contract has no set-aside designation and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and critical...
- The Defense Logistics Agency awarded a $7,352.49 delivery order to AmerisourceBergen Drug Corp for 30-unit supplies of Erleada 240 mg tablets, with a completion date of November 24, 2025. This non-set-aside, firm fixed-price contract represents a competitive award for pharmaceutical supply to support federal medical procurement needs. The order will be fulfilled from the vendor's Conshohocken, Pennsylvania location, where AmerisourceBergen maintains its corporate operations as a major...
- The Defense Logistics Agency awarded a $15,931.60 firm fixed-price delivery order to AmerisourceBergen Drug Corp for 120 tablets of Erleada 60 mg on December 17, 2025, with an ultimate completion date of January 9, 2026. The contract, which is not set-aside, will be performed at the vendor's corporate office in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a comprehensive...
- The Defense Logistics Agency awarded a delivery order valued at $7,558.78 to AmerisourceBergen Drug Corp for Erleada 60 mg tablets (120 count) on September 2, 2025, with an ultimate completion date of September 23, 2025. This firm fixed price delivery order represents a non-competitive, non-set-aside award under the company's existing Indefinite Delivery Contract with DLA Troop Support Medical. The contract will be performed at AmerisourceBergen's corporate headquarters in Conshohocken,...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on December 30, 2025, for the supply of Erleada 60 mg tablets (120-count units) with a ceiling value of $7,965.80 and a firm fixed-price contract type. This delivery order, which is not set-aside, is expected to be completed by January 22, 2026, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award represents a child contract issued under...
- The Defense Logistics Agency awarded a $29,409.96 firm fixed-price delivery order to AmerisourceBergen Drug Corp on August 18, 2025, for the supply of Erleada 240 mg tablets in quantities of 30 units. The contract, which is not set-aside, will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania, with an ultimate completion date of September 9, 2025. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop...
- The Defense Logistics Agency awarded a $7,748.39 delivery order to AmerisourceBergen Drug Corp for 30 tablets of Erleada 240 mg, with a completion deadline of January 22, 2026. This is a firm fixed price contract with no set-aside designation, issued competitively to the pharmaceutical distributor's Corporate Office location in Conshohocken, Pennsylvania. The award represents a single delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support...
- SPE2DR25D3015Indefinite Delivery Contract
- SPE2DR25D3015-SPE2DR26F4FZ9Delivery Order
The Defense Logistics Agency awarded a delivery order valued at $7,748.39 to AmerisourceBergen Drug Corp for the supply of Erleada 240 mg tablets (30-count units) on January 6, 2026, with an ultimate completion date of January 28, 2026. This competitively awarded, firm fixed-price contract carries no set-aside designation and represents a task order under AmerisourceBergen's parent company Cencora, Inc.'s substantial Indefinite Delivery Contract with DLA Troop Support Medical. That underlying IDC, valued at $999,999,999.00 and extending through December 2031, serves as a comprehensive global pharmaceutical support vehicle enabling the delivery of a broad range of pharmaceutical products and medical supplies to support military healthcare programs worldwide. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor and critical federal medical procurement vendor serving military and veteran healthcare systems. The company's federal contract portfolio demonstrates extensive experience fulfilling diverse pharmaceutical requirements across multiple therapeutic domains, including specialty medications, brand-name and generic drugs, and medical devices. This delivery order for Erleada, a prostate cancer treatment, exemplifies the company's role in supplying specialized oncology medications to support Department of Defense healthcare operations and the broader military treatment facility network.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $7.7k | 1/5/26 |